摘要
目的:观察布地奈德联合特布他林雾化吸入治疗毛细支气管炎的临床疗效。方法:将162例毛细支气管炎患儿以随机抽样法分成对照组80例和治疗组82例。2组患者均常规给予抗感染、抗病毒、平喘、化痰、吸氧等治疗,治疗组在此基础上加用布地奈德混悬液联合特布他林雾化液气泵雾化吸入,比较2组疗效并进行统计学处理。结果:治疗组患者在咳嗽消失、喘憋缓解、哮鸣音和肺部啰音消失时间、病程缩短方面明显优于对照组(P<0.01);治疗组(治愈率为93.90%)疗效优于对照组(治愈率为61.25%)(P<0.01)。结论:布地奈德联合特布他林雾化吸入治疗毛细支气管炎疗效好,值得临床推广。
OBJECTIVE：To observe the clinical efficacy of budesonide plus terbutaline （aerosol inhalation） for bronchiolitis. METHODS： 162 pediatric patients with bronchiolitis were randomly divided into control group （n = 80） and trial group （ n = 82 ）. Both groups received anti-infective, antiviral, antiasthmatic, phlegm-dissipating therapy plus oxygen inhalation; however, the trial group was administered with add-on budesonide suspension plus terbutaline atomized liquid （aerosol inhalation）. The clinical efficacy was compared between the two groups and the data were treated statistically. RESULTS： The trial group was significantly better than the control group with regard to the extinction time of cough, wheezing and lung rales, relief of asthmatic suffocation, shortening of course of treatment （P 〈0. 01） and the cure rate in the trial group was higher than in the control group （93.90% vs. 61.25% ） （P 〈 0. 01）. CONCLUSION： Budesonide combined terbutaline （aerosol inhalation） was proved to be of good clinical efficacy for bronehiolitis and thus the therapy is worth of clinical popularization.
出处
《中国医院用药评价与分析》
2013年第4期363-365,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
